These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1826891)

  • 1. Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril.
    Spieker C; Zidek W; Vetter H; Rahn KH
    J Int Med Res; 1991; 19(1):39-43. PubMed ID: 1826891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ramipril on ambulatory blood pressure: a multicenter trial.
    Burris JF
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S131-3. PubMed ID: 1725022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.
    Mroczek WJ
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S147-9. PubMed ID: 1725028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.
    Schnaper HW
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S128-30. PubMed ID: 1725021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term blood pressure measurement for evaluating the first dose response of captopril and ramipril in patients with a stimulated renin system].
    Lüders S; Schrader J; Schoel G; Ruschitzka F; Scheler F
    Z Kardiol; 1992; 81 Suppl 2():41-4. PubMed ID: 1387500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
    Bauer B; Lorenz H; Zahlten R
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S70-4. PubMed ID: 2474109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
    Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
    Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
    Stumpe KO; Overlack A; Kolloch R; Schatz J; Witte PU; Pahnke K
    Klin Wochenschr; 1986 Jun; 64(12):558-62. PubMed ID: 3016405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension.
    Tochikubo O; Asahina S; Kaneko Y
    Am J Cardiol; 1987 Apr; 59(10):83D-85D. PubMed ID: 3034039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.
    Erhard W; Lindner U; Krall H; Breitstadt A; Pfeiffer C
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S160-4. PubMed ID: 1725032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
    Kaneko Y; Omae T; Yoshinaga K; Iimura O; Inagaki Y; Ishii M; Saruta T; Yamada K; Kumahara Y; Ito K
    Am J Cardiol; 1987 Apr; 59(10):86D-91D. PubMed ID: 3034040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
    Böhm RO; van Baak MA; Rahn KH
    Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 24-hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Ramipril Multicenter Study Group.
    McCarron D
    Clin Cardiol; 1991 Sep; 14(9):737-42. PubMed ID: 1835914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive efficacy, tolerance, and safety of ramipril in young vs. old patients: a retrospective study.
    Saalbach R; Wochnik G; Mauersberger H; Cairns V; Breitstadt A; Rangoonwala B
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S134-6. PubMed ID: 1725023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    Am J Cardiol; 1988 Aug; 62(4):239-45. PubMed ID: 2969671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.
    Heidbreder D; Froer KL; Bauer B; Cairns V; Breitstadt A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S169-73. PubMed ID: 1725034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.
    Predel HG; Düsing R; Bäcker A; Kipnowski J; Kramer HJ
    Am J Cardiol; 1987 Apr; 59(10):143D-148D. PubMed ID: 3034023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.
    Villamil AS; Cairns V; Witte PU; Bertolasi CA
    Am J Cardiol; 1987 Apr; 59(10):110D-114D. PubMed ID: 3034017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.